Cagrilintide

Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It is engineered with a fatty-acid side chain that binds serum albumin, extending its half-life to support once-weekly research dosing.

If GLP-1 is the 'I'm not hungry' hormone, amylin is the 'I'm actually full' hormone. Cagrilintide is the long-acting version researchers pair with semaglutide to hit appetite from two angles at once.

Activates amylin and calcitonin receptors, slowing gastric emptying, suppressing glucagon, and signaling satiety in the hindbrain. Its mechanism is complementary to GLP-1 agonists, which is why combination research has drawn so much attention.

• •Obesity and weight-loss models
• •CagriSema (Cagrilintide + Semaglutide) trials
• •Gastric emptying studies
• •Satiety and food-intake research
• •Combination therapy with GLP-1 agonists

Heavily discussed in GLP-1 communities as the next frontier after semaglutide and tirzepatide. The 'CagriSema' combination is the focal point — Phase III data has shown weight-loss percentages competitive with or exceeding tirzepatide in some endpoints.

“Semaglutide's tag-team partner for appetite.”

The defining stack is Cagrilintide + Semaglutide (CagriSema). Sometimes discussed alongside tirzepatide as comparators.

Cagrilintide is a long-acting amylin analog studied alongside GLP-1 agonists for additive satiety, gastric slowing, and weight-loss research.